ACCESS Newswire·Oct 16, 2025, 7:30 AM ET

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

MIRA Pharmaceuticals announced preclinical data showing oral Mira-55 fully normalized pain & significantly reduced inflammation in an animal model.
Oral Mira-55 outperformed injected morphine by providing direct anti-inflammatory effects & superior pain normalization without sedation or opioid risks.
The study marks the first direct measurement of inflammation alongside pain in the Mira-55 program, confirming a CB2 receptor-mediated mechanism.
Results support IND plans & position Mira-55 as a dual-acting non-opioid therapy addressing both the cause & perception of pain.
The global non-opioid pain market was valued at $45.3 billion in 2024 & is projected to reach $70.3 billion by 2030.
The U.S. DEA determined Mira-55 is not a controlled substance due to its non-psychoactive profile.
Prior studies indicate Mira-55 also enhances memory & reduces anxiety-related behavior beyond its analgesic effects.
MIRA's pipeline includes Mira-55, Ketamir-2, & SKNY-1, with the company headquartered in Miami, Florida.